Professional
Added to YB: 2024-11-27
Pitch date: 2024-11-22
EWTX [bullish]
Edgewise Therapeutics, Inc.
-27.05%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Market Cap
$2.4B
Pitch Price
$32.38
Price Target
45.00 (+91%)
Dividend
N/A
EV/EBITDA
-10.41
P/E
-14.48
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Show full summary:
Edgewise Therapeutics: Multiple Upcoming Catalysts Will Keep You On The Edge; Initiate Outperform
EWTX: Multiple catalysts for sevasemten (BMD/DMD) & EDG-7500 (HCM). Ph2 BMD data Dec'24 key for AA. Modeling 2027 launch, $3.4B peak sales '35. EDG-7500 promising safety vs CMIs. $45 PT based on DCF. Risks: indirect MOA, biomarker approval, differentiation from CMIs.